NCT01679639View on ClinicalTrials.gov

A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Healthy Volunteer
Interventions
DRUG

aleglitazar

Single dose of aleglitazar in Periods 1, 2, 3

DRUG

rifampicin

Single dose in Periods 1 and 2; multiple doses in Period 3

Trial Locations (1)

M13 9WL

Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01679639 - A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers | Biotech Hunter | Biotech Hunter